+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comparative pharmacokinetic and pharmacodynamic properties of oral and intravenous (+)-sotalol in healthy volunteers



Comparative pharmacokinetic and pharmacodynamic properties of oral and intravenous (+)-sotalol in healthy volunteers



Journal of Pharmacy and Pharmacology 46(7): 600-605



The pharmacokinetic and pharmacodynamic properties of (+)-sotalol (BMY-5763) were studied to analyse the relationship between plasma concentration and QTc prolongation in healthy male volunteers given single oral doses of 50, 100, 200 and 300 mg, repeated oral doses of 200 mg twice daily for 6.5 days, and single intravenous doses of 1.0 and 1.5 mg kg-1. The plasma concentration of (+)-sotalol peaked about 3 h after oral administration and declined with a half-life of 7.9-9.7 h. The Cmax and AUC showed dose-related increases, while the urinary recovery as the unchanged form remained constant (66-68% of the dose). During repeated oral administration the plasma concentration of (+)-sotalol reached almost a steady state on the 3rd day and there was no change in renal clearance of (+)-sotalol measured on the 1st, 4th and 7th days. After intravenous administration, (+)-sotalol in plasma decreased bi-exponentially with a terminal half-life of 7.6-8.3 h and the urinary recovery as unchanged drug amounted to 84-88% of the dose. The increase in QT interval was significant after a single oral administration except for the lowest dose, and regression analysis revealed a significant correlation between QTc interval and concentration of (+)-sotalol in plasma. The same correlation was evident with repeated oral doses on the 1st, 4th and 7th days. In the case of single intravenous administrations of (+)-sotalol, a combined pharmacokinetic-pharmacodynamic model was attempted by assuming an effect compartment.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 045584593

Download citation: RISBibTeXText

PMID: 7996391


Related references

Pharmacokinetic and pharmacodynamic properties of dl-sotalol administered orally in healthy male volunteers. Japanese Journal of Pharmacology 71(SUPPL 1): 294P, 1996

Pharmacokinetic and pharmacodynamic profile of oral and intravenous meta-chlorophenylpiperazine in healthy volunteers. Journal of Clinical Psychopharmacology 18(4): 289-295, 1998

Population Pharmacokinetic-Pharmacodynamic Model of Oral Fludrocortisone and Intravenous Hydrocortisone in Healthy Volunteers. Aaps Journal 19(3): 727-735, 2017

Pharmacokinetic-pharmacodynamic modelling of intravenous and oral topiramate and its effect on phonemic fluency in adult healthy volunteers. British Journal of Clinical Pharmacology 79(5): 820-830, 2016

Pharmacokinetic-Pharmacodynamic Modeling of Intravenous and Oral Topiramate and Its Effect on the Symbol-Digit Modalities Test in Adult Healthy Volunteers. Journal of Clinical Pharmacology 56(6): 714-722, 2017

A pharmacokinetic-pharmacodynamic model of d-sotalol Q-Tc prolongation during intravenous administration to healthy subjects. Journal of Clinical Pharmacology 37(9): 799-809, 1998

A Pharmacokinetic-Pharmacodynamic Model of d-Sotalol Q-Tc Prolongation During Intravenous Administration to Healthy Subjects. The Journal of Clinical Pharmacology 37(9): 799-809, 1997

Pharmacokinetic and pharmacodynamic properties of a new thromboxane receptor antagonist (Z-335) after single and multiple oral administrations to healthy volunteers. Journal of Clinical Pharmacology 42(7): 782-790, 2002

Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study. Clinical Therapeutics 29(8): 1620-1631, 2007

Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers. Clinical Therapeutics 31(2): 286-298, 2009

Separation of the pharmacokinetic pharmacodynamic properties of oral and iv adinazolam mesylate and n demethyladinazolam mesylate in healthy volunteers. Drug Investigation 4(2): 155-165, 1992

Separation of the Pharmacokinetic/Pharmacodynamic Properties of Oral and IV Adinazolam Mesylate andN-Desmethyladinazolam Mesylate in Healthy Volunteers. Clinical Drug Investigation 4(2): 155-165, 1992

Pharmacokinetic and pharmacodynamic pilot study of intravenous fk506 in healthy volunteers. Pharmaceutical Research (New York) 8(10 SUPPL): S61, 1991

Pharmacokinetic and Pharmacodynamic Modeling Analysis of Intravenous Esomeprazole in Healthy Volunteers. Journal of Clinical Pharmacology 56(7): 816-826, 2017

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clinical Therapeutics 28(1): 55-72, 2006